SCHEMBL724611

SCHEMBL724611

CCOC(=O)CC(c1ccccc1)c1cc(Br)ccc1OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.46
LMNA P02545 3/20 0.46
MAPT P10636 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
LRRK2 Q5S007 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
ALDH1A1 P00352 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
HTT P42858 1/20 0.44
CCR5 P51681 1/20 0.44
PTGER1 P34995 2/20 0.44
CYP1A2 P05177 1/20 0.44
HTR7 P34969 1/20 0.43
HTR6 P50406 1/20 0.43
USP2 O75604 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1355279 0.89 HTT (0.50) LMNASMN1; SMN2LRRK2KDM4EALDH1A1
SCHEMBL12293726 0.86 CCR5 (0.47) NPSR1LMNAMAPTSMN1; SMN2TDP1
SCHEMBL12674632 0.86 CYSLTR2 (0.46) NPSR1LMNAMAPTSMN1; SMN2TDP1
SCHEMBL2167632 0.86 KMT2A (0.47) LMNASMN1; SMN2LRRK2ALDH1A1HTT
SCHEMBL1783943 0.86 KMT2A (0.47) LMNASMN1; SMN2LRRK2ALDH1A1HTT
SCHEMBL2166135 0.86 KMT2A (0.47) LMNASMN1; SMN2LRRK2ALDH1A1HTT
SCHEMBL2167258 0.84 LRRK2 (0.46) LMNALRRK2ALDH1A1HTTCCR5
SCHEMBL12403885 0.84 LRRK2 (0.46) LMNALRRK2ALDH1A1HTTCCR5
SCHEMBL15148415 0.84 LRRK2 (0.46) LMNALRRK2ALDH1A1HTTCCR5
SCHEMBL2167293 0.83 LMNA (0.47) NPSR1LMNAMAPTSMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012678-B2 Processes for the preparation of fesoterodine CADILA HEALTHCARE LIMITED (IN) 2015-04-21 US disclosed
US-20130197260-A1 PROCESSES FOR THE PREPARATION OF FESOTERODINE CADILA HEALTHCARE LIMITED (IN) 2013-08-01 US disclosed
WO-2012025941-A2 PROCESSES FOR THE PREPARATION OF FESOTERODINE CADILA HEALTHCARE LIMITED (IN) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130197260-A1 PROCESSES FOR THE PREPARATION OF FESOTERODINE QDPR, FES, SULT1A1 NPSR1 56/4885LMNA 4862/4885MAPT 3157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.